Given the possible distress caused by the disclosure of the biomarker results and the lack of preventive treatments, we also strongly advocate that people who do not yet have cognitive impairments should not be tested or diagnosed based on plasma (or PET) biomarkers in clinical settings, and restricting the use of plasma p‐tau217, CSF p‐tau217, and tau PET to research settings and specialized clinics where counseling is available. Here, MAPT is linked to Cognitive impairment.